M M Peña-Vilabelda1, Z García-Casado2, C Requena1, V Traves3, J A López-Guerrero2, C Guillén1, R Kumar4, E Nagore5. 1. Servicio de Dermatología, Instituto Valenciano de Oncología, Valencia, España. 2. Unidad de Biología Molecular; Instituto Valenciano de Oncología, Valencia, España. 3. Servicio de Anatomía Patológica, Instituto Valenciano de Oncología, Valencia, España. 4. Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Alemania. 5. Servicio de Dermatología, Instituto Valenciano de Oncología, Valencia, España; Universidad Católica de Valencia, Valencia, España. Electronic address: eduardo_nagore@ono.com.
Abstract
INTRODUCTION: Patients with cutaneous melanoma who are carriers of polymorphisms in the melanocortin 1 receptor gene (MC1R) have distinctive clinical characteristics. The objective of this study was to determine the clinical characteristics associated with differing degrees of functional impairment of the melanocortin 1 receptor, as determined by the number and type (R and r) of MC1R polymorphisms. MATERIAL AND METHODS: In total, 1044 consecutive patients with melanoma diagnosed in our hospital after January 2000 were selected from the melanoma database. These patients were divided into 3 groups according to a score based on nonsynonymous MC1R polymorphisms. The frequencies of epidemiologic, phenotypic, and histologic variables and personal and family history of cancer were compared. RESULTS: Patients with a score of 3 or more were more likely to develop melanoma before the age of 50 years (odds ratio [OR]=1.47), have a tumor on the head or neck (OR=3.04), have a history of basal cell carcinoma or cutaneous squamous cell carcinoma (OR=1.70), have atypical nevi (OR=1.74), and have nevi associated with the melanoma (OR=1.87). CONCLUSIONS: The use of a scoring system for MC1R polymorphisms allowed us to identify associations between the degree of functional impairment of the melanogenesis pathway and the clinical characteristics of the patients and melanoma presentation.
INTRODUCTION:Patients with cutaneous melanoma who are carriers of polymorphisms in the melanocortin 1 receptor gene (MC1R) have distinctive clinical characteristics. The objective of this study was to determine the clinical characteristics associated with differing degrees of functional impairment of the melanocortin 1 receptor, as determined by the number and type (R and r) of MC1R polymorphisms. MATERIAL AND METHODS: In total, 1044 consecutive patients with melanoma diagnosed in our hospital after January 2000 were selected from the melanoma database. These patients were divided into 3 groups according to a score based on nonsynonymous MC1R polymorphisms. The frequencies of epidemiologic, phenotypic, and histologic variables and personal and family history of cancer were compared. RESULTS:Patients with a score of 3 or more were more likely to develop melanoma before the age of 50 years (odds ratio [OR]=1.47), have a tumor on the head or neck (OR=3.04), have a history of basal cell carcinoma or cutaneous squamous cell carcinoma (OR=1.70), have atypical nevi (OR=1.74), and have nevi associated with the melanoma (OR=1.87). CONCLUSIONS: The use of a scoring system for MC1R polymorphisms allowed us to identify associations between the degree of functional impairment of the melanogenesis pathway and the clinical characteristics of the patients and melanoma presentation.
Authors: Nicholas J Taylor; Klaus J Busam; Lynn From; Pamela A Groben; Hoda Anton-Culver; Anne E Cust; Colin B Begg; Terence Dwyer; Richard P Gallagher; Stephen B Gruber; Irene Orlow; Stefano Rosso; Nancy E Thomas; Roberto Zanetti; Timothy R Rebbeck; Marianne Berwick; Peter A Kanetsky Journal: PLoS One Date: 2015-03-19 Impact factor: 3.240